Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Expectations for June Phase 2 PEARL Trial

March 29, 2012 8:40 AM EDT
Get Alerts ANTH Hot Sheet
Price: $0.60 --0%

Rating Summary:
    8 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 16 | New: 10
Trade ANTH Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $6.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on blisibimod (B--mod) clinical and commercial potential in lupus. We expect B-mod, ANTH’s BAFF peptibody for lupus, will yield positive data from the Phase 2 PEARL trial in June and ANTH to start the Phase 3 Chablis trial in Q1/13. ANTH may start Phase 2 B-mod trials in other lupus-related B cell disorders to leverage market potential and diversify clinical risk."

For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.

Shares of Anthera Pharma closed at $2.32 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment